Tenax Therapeutics has acquired PH Precision Med (PHPM), a private biotech focused on developing imatinib as a treatment for pulmonary arterial hypertension (PAH). “The acquisition of PHPM immediately expands Tenax’s pipeline to include a second de-risked Phase 3 ready candidate with the potential to be the first disease modifying treatment of pulmonary arterial hypertension,” Anthony DiTonno, Tenax’s CEO, said in a press release. Imatinib is marketed as Gleevec and used to treat certain types of…

You must be logged in to read/download the full post.